Digicann Ventures Inc. operates in the cannabis industry, focusing on specialty and generic drug manufacturing. The company faces significant concerns, notably a very low current ratio of 0.08, indicating liquidity issues, and a negative return on assets of -148.7%, suggesting poor operational efficiency. With a market cap of only $360.83K and a stock price of $0.01, the valuation appears weak, raising questions about its financial viability. Overall, while the cannabis sector has growth potential, Digicann's financial metrics raise red flags for investors.
Loading financial metrics...
Company has $118K in cash but burned $74K last quarter. At this burn rate, only 1.6 quarters of runway remain without additional financing.
Company posted a loss of $-655K over the last year, representing Infinity% of revenue.
Debt of $1.1M is 9.3x the company's cash position of $118K.
Operating cash flow has been negative for 3 consecutive quarters, burning $297K over the last year.
No significant opportunities identified
Based on current financial metrics
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2025-Q3 (September 30, 2025)